Inhibrx Biosciences (INBX) Interest Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Interest Expenses data on file, last reported at $5.8 million in Q4 2025.

• On a quarterly basis, Interest Expenses rose 192.7% year-over-year to $5.8 million in Q4 2025; TTM through Dec 2025 was $13.2 million, a 14.95% decrease from a year earlier, with the FY2025 full-year figure at $220.3 million, up 911.25% from the prior year.
• Interest Expenses for Q4 2025 stood at $5.8 million, down from $8.0 million in the prior quarter.
• Over the last five years, Interest Expenses for INBX reached as high as $9.3 million in Q1 2025 and fell as low as $2.0 million in Q4 2024.
• Historically, Interest Expenses has averaged $7.2 million across 3 years, with a median of $8.1 million in 2024.
• Across the five-year window, Interest Expenses slumped 75.91% in 2024 and soared 192.7% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $8.2 million in 2023, then slumped by 75.91% to $2.0 million in 2024, then soared by 192.7% to $5.8 million in 2025.
• Per Business Quant data, the three most recent Interest Expenses figures were $5.8 million in Q4 2025, $8.0 million in Q3 2025, and $8.7 million in Q2 2025.